What is the appropriate management for an 86‑year‑old patient with stage 4 chronic kidney disease (eGFR ≈ 25 mL/min/1.73 m²), mild anemia (hemoglobin 112 g/L), low magnesium (0.64 mmol/L), modest albuminuria (albumin‑creatinine ratio ≈ 28 mg/g), and elevated alkaline phosphatase?

Management of Stage 4 CKD with Mild Anemia and Low Magnesium in an 86-Year-Old

Start an SGLT2 inhibitor immediately (empagliflozin 10 mg, dapagliflozin 10 mg, or canagliflozin 100 mg daily), initiate or uptitrate a RAS inhibitor to maximum tolerated dose, correct the magnesium deficiency with oral supplementation, and address the mild anemia after excluding reversible causes. 1, 2

Immediate Nephroprotective Therapy

SGLT2 Inhibitor Initiation

• Begin an SGLT2 inhibitor now because this patient has eGFR 25 mL/min/1.73 m² (above the threshold of 20) and ACR 28 mg/g falls in the 20-45 range (moderately increased albuminuria when eGFR is this low), making SGLT2i therapy a Grade 2B recommendation even without diabetes. 1, 2
• Continue the SGLT2 inhibitor even if eGFR drops below 20 mL/min/1.73 m² during follow-up, as this represents hemodynamic benefit rather than harm. 1
• Expect a reversible 3-5 mL/min/1.73 m² eGFR decline within the first 2-4 weeks; this predicts long-term kidney protection and is not an indication to stop therapy. 2
• Withhold temporarily only during prolonged fasting, surgery, or acute critical illness to reduce ketoacidosis risk. 1

RAS Inhibitor Management

• Initiate an ACE inhibitor (lisinopril 10-40 mg daily or enalapril 10-40 mg daily) or ARB (losartan 50-100 mg daily) and titrate to the maximum tolerated dose to achieve renoprotection, even though ACR is only 28 mg/g. 1, 2, 3
• Continue RAS inhibition despite eGFR 25 mL/min/1.73 m² because KDIGO explicitly recommends continuation even when eGFR falls below 30. 1, 3, 4
• Monitor serum creatinine and potassium 2-4 weeks after starting or dose escalation; accept creatinine rises up to 30% as expected and nephroprotective. 1, 3, 4
• Reduce or discontinue RAS inhibitor only if:
  • Creatinine rises >30% within 4 weeks 1, 3
  • Symptomatic hypotension persists despite management 1, 3
  • Hyperkalemia remains uncontrolled after potassium-lowering measures 1, 3
  • eGFR falls below 15 mL/min/1.73 m² with uremic symptoms 1, 3

Mineralocorticoid Receptor Antagonist Consideration

• Do not add finerenone at this time because the patient's eGFR is exactly 25 mL/min/1.73 m² (the lower threshold) and ACR 28 mg/g is below the 30 mg/g cutoff for nonsteroidal MRA therapy. 1
• Reassess for finerenone if ACR rises above 30 mg/g on repeat testing and potassium remains ≤4.8 mmol/L, at which point 10 mg daily would be appropriate. 1

Electrolyte and Metabolic Correction

Magnesium Replacement

• Prescribe oral magnesium supplementation (magnesium oxide 400-800 mg daily or magnesium citrate 200-400 mg daily) to correct the low magnesium of 0.64 mmol/L (normal 0.7-1.0 mmol/L). 1
• Recheck magnesium in 4-6 weeks after initiating supplementation to confirm normalization.
• Monitor for diarrhea, the most common side effect of oral magnesium, and adjust formulation or dose accordingly.

Metabolic Acidosis Screening

• Measure serum bicarbonate because stage 4 CKD frequently causes metabolic acidosis, which accelerates CKD progression and worsens bone disease. 1
• If bicarbonate <18 mmol/L, initiate sodium bicarbonate 650-1300 mg three times daily to prevent clinical complications. 1
• Monitor blood pressure, potassium, and fluid status when treating acidosis to avoid sodium-related adverse effects. 1

Anemia Evaluation and Management

Diagnostic Workup

• Obtain complete iron studies (serum iron, TIBC, ferritin, transferrin saturation), vitamin B12, folate, and reticulocyte count to identify the cause of hemoglobin 112 g/L (mild anemia). 5, 6
• Check for occult blood loss (stool guaiac testing) and review medications for bone marrow suppressants or nephrotoxins. 5, 7
• Recognize that CKD stage 4 itself causes erythropoietin deficiency, making anemia of CKD the most likely diagnosis after excluding other causes. 5, 8, 6

Iron Supplementation

• If ferritin <100 ng/mL or transferrin saturation <20%, start oral iron (ferrous sulfate 325 mg daily or polysaccharide iron complex 150 mg daily) as first-line therapy for iron deficiency. 6, 9
• Consider intravenous iron (iron sucrose 200 mg or ferric carboxymaltose 500-1000 mg) if oral iron is not tolerated or ineffective after 3 months. 6, 9

Erythropoiesis-Stimulating Agent Consideration

• Hemoglobin 112 g/L does not mandate immediate ESA therapy because current guidelines recommend individualizing the decision based on symptoms, transfusion risk, and rate of decline. 6, 9
• If hemoglobin falls below 100 g/L or the patient develops symptomatic anemia (fatigue, dyspnea, reduced functional capacity), initiate an ESA (epoetin alfa 50-100 units/kg subcutaneously weekly or darbepoetin 0.45 mcg/kg every 2 weeks) after correcting iron deficiency. 6, 9
• Target hemoglobin 100-115 g/L to balance symptom relief against cardiovascular and thrombotic risks associated with higher targets. 6, 9
• ESAs remain first-line over HIF-prolyl hydroxylase inhibitors due to longer safety experience and persistent cardiovascular concerns with HIF-PHIs. 9

Monitoring Strategy

Short-Term (2-4 Weeks After Medication Changes)

• Recheck serum creatinine, potassium, and blood pressure after starting SGLT2 inhibitor or RAS inhibitor. 1, 2, 4
• Do not stop therapy for expected eGFR dips or creatinine rises ≤30%, as these changes predict long-term benefit. 1, 2, 4

Long-Term (Every 3-6 Months)

• Repeat eGFR, ACR, hemoglobin, potassium, bicarbonate, calcium, phosphate, and PTH to monitor CKD progression and complications. 1, 2, 10
• Aim for ≥30% reduction in albuminuria if ACR rises above 300 mg/g on subsequent testing. 2

Additional Cardiovascular Risk Reduction

Blood Pressure Management

• Target blood pressure <120/80 mmHg if tolerated to slow CKD progression and reduce cardiovascular events. 2, 10
• Use the RAS inhibitor and add a diuretic (furosemide 20-40 mg daily) or calcium channel blocker (amlodipine 5-10 mg daily) if additional agents are needed. 10

Lipid Management

• Initiate statin therapy (atorvastatin 20-40 mg daily or rosuvastatin 10-20 mg daily) because the patient is ≥50 years old with CKD, meeting Grade 1 recommendation criteria. 2, 10

Bone-Mineral Disorder Screening

• Measure serum calcium, phosphate, PTH, and 25-hydroxyvitamin D because the elevated alkaline phosphatase (126 U/L) may reflect secondary hyperparathyroidism or CKD-mineral bone disorder. 10
• If PTH is elevated, restrict dietary phosphate and consider phosphate binders (calcium acetate 667 mg with meals or sevelamer 800 mg three times daily) if serum phosphate is high. 10
• Supplement vitamin D (cholecalciferol 1000-2000 IU daily) if 25-hydroxyvitamin D is <30 ng/mL. 10

Nephrology Referral

• Refer to nephrology now because eGFR 25 mL/min/1.73 m² (stage 4 CKD) meets the threshold for specialist co-management to prepare for potential kidney replacement therapy and optimize medical management. 2, 10, 11
• Urgent referral is indicated if eGFR continues to decline rapidly, albuminuria worsens despite therapy, or the patient develops uremic symptoms (nausea, pruritus, altered mental status). 2, 10

Common Pitfalls to Avoid

• Do not withhold SGLT2 inhibitors or RAS inhibitors because of advanced CKD; both are safe and beneficial at eGFR 25 mL/min/1.73 m². 1, 3
• Do not stop RAS inhibitors for modest creatinine rises <30%, as this reflects intraglomerular pressure reduction and predicts long-term kidney protection. 1, 3, 4
• Do not combine an ACE inhibitor with an ARB or direct renin inhibitor, as dual RAS blockade increases harm without added benefit. 3, 4
• Do not target hemoglobin >115 g/L with ESAs, as higher targets increase cardiovascular events and mortality. 6, 9
• Do not overlook hyperkalemia management; use dietary restriction, loop diuretics, or potassium binders rather than discontinuing nephroprotective RAS inhibitors. 1